Intra-arterial versus intra-venous thrombolysis within and after the first 3 hours of stroke onset

Archives of Medical Science

Volumn 6, Issue 3, 2010, Pages 303-315

  Padma, Srivastava ^a   Majaz, Moonis ^b  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b MEMORIAL MEDICAL CENTER   (United States)

Author keywords

Intra arterial; Intravenous; Ischemic stroke; Re canalization; Thrombolysis

Indexed keywords

ABCIXIMAB; ALTEPLASE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; DESMOTEPLASE; FIBRINOLYTIC AGENT; HEPARIN; MICROPLASMIN; PLACEBO; PLASMIN; PROUROKINASE; RETEPLASE; STAPHYLOKINASE; STREPTOKINASE; TENECTEPLASE; UNCLASSIFIED DRUG; UROKINASE;

BASILAR ARTERY; BLOOD CLOT LYSIS; BLOOD VESSEL OCCLUSION; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FIBRINOLYTIC THERAPY; HUMAN; INTERNAL CAROTID ARTERY; MAGNETIC RESONANCE ANGIOGRAPHY; MIDDLE CEREBRAL ARTERY; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PERFUSION WEIGHTED IMAGING; POSITRON EMISSION TOMOGRAPHY; RECANALIZATION; REVIEW; RHEOLYTIC THROMBECTOMY; TREATMENT OUTCOME; VERTEBRAL ARTERY;

EID: 77954252861     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: 10.5114/aoms.2010.14248     Document Type: Review

References (84)

1. Astrup J, Symon L, Branston NM, Lassen NA. Cortical evoked potential and extracellular K+ and H+ at critical levels of brain ischemia. Stroke 1977; 8: 51-7. (Pubitemid 8025387)
2. Heiss WD. Progress in cerebrovascular disease: flow thresholds of functional and morphological damage of brain-tissue. Stroke 1983; 14: 329-31.
3. Hacke W, Del Zoppo GJ, Harker LA. Thrombosis and cerebrovascular disease. In: Recent advances in diagnosis and management of stroke. Poeck K, Ringelstein EB, Tacke W (eds). Springer-Verlag, USA 1987; 59-64.
4. Fieschi C, Argentino C, Lenzi GI, et al. Clinical and instrumental evaluation of patients with ischemic stroke within the first six hours. J Neurol Sci 1989; 91: 311-21. (Pubitemid 19170247)
5. The National Institute of Neurological Disorders and stroke rt-PA stroke study group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581-7.
6. Hoffman JR. Tissue plasminogen activator for acute ischemic stroke: is the CAEP position statement too negative? Can J Emerg Med CJEM 2001; 3.
7. Mann J. Truths about the NINDS study: setting the record straight. West J Med 2002; 176: 192-4. (Pubitemid 37505031)
8. Adams HP Jr, Davis PH, Leira EC, et al. Baseline NIH Stroke Scale score strongly predicts outcome after stroke: a report of the Trial of Org 10172 in Acute Stroke Treatment (TOAST). Neurology 1999; 53: 126-31.
9. Wolpert SM, Bruckmann H, Greenlee R, et. al. Neuroradiologic evaluation of patients with acute stroke treated with recombinant tissue plasminogen activator. The rTPA Acute Stroke Study Group. AJNR Am J Neuroradiol 1993; 14: 3-13.
10. Mori E, Yoneda Y, Tabuchi M, et al. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology 1992; 42: 976-82.
11. del Zoppo GM, Poeck K, Pessin MS, et al. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol 1992; 32: 78-86.
12. Lee KY, Han SW, Kim SH, et al. Early recanalization after intravenous administration of recombinant tissue plasminogen activator as assessed by pre and postthrombolytic angiography in acute iscehmic stroke patients. Stroke 2007; 38: 192-3.
13. Alexondrov AV, Molina CA, Grotta JC, et al. Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke. N Engl J Med 2004; 351: 2170-8.
14. del Zoppo GJ, Higashida RT, Furlan AJ, Pessin MS, Rowley HA, Gent M. PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. Stroke 1998; 29: 4-11. (Pubitemid 28046933)
15. Furlan A, Higashida R, Wechsler L, et al. Intra-arterial prourokinase for acute ischemic stroke: the PROACT II study: a randomized controlled trial: prolyse in acute cerebral thromboembolism. JAMA 1999; 282: 2003-11.
16. Leker RR, Eichel R, Rafaeli G, Ben-Hur T. Novel therapies for acute ischemic stroke. Isr Med Assoc J 2006; 8: 788-92. (Pubitemid 44842649)
17. Qureshi AI, Ali Z, Suri MF, et al. Intra-arterial third generation recombinant tissue plasminogen activator (reteplaase) for acute ischemic stroke. Neurosurgery 2001; 49: 41-50. (Pubitemid 32552580)
18. Qureshi AI, Pande RU, Kim SH, Hanel RA, Kirmani JF, Yahia AM. Third generation thrombolytics for the treatment of ischemic stroke. Curr Opin Investig Drugs 2002; 3: 1729-32.
19. Lachak PA, Song D, Wei J, Zivin JA. Coadministration of NXY-059 and tenecteplase six hours following embolic strokes in rabbits improves clinical rating scores. Exp Neurol 2004; 188: 279-85. (Pubitemid 38891588)
20. Cornu C, Boutitie F, Candelise L, et al. Streptokinase in acute ischemic stroke: an individual patient data metaanalysis: The Thrombolysis in Acute Stroke Pooling Project. Stroke 2000; 31: 1555-60.
21. Furlan AJ, Eyding D, Albers GW, et al. Dose escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): Evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke 2006; 37: 1227-31. (Pubitemid 43731867)
22. Hacke W, Albers G, Al-Rawi Y, et al. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 19-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 2005; 36: 66-73.
23. Collen D, Lijnen HR. Thrombolytic agents. Thromb Haemost 2005; 93: 627-30.
24. Sugg RM, Noser EA, Shaltoni HM, et al. Intra-arterial reteplase compared to urokinase for thrombolytic recanalization in acute ischemic stroke. AJNR Am J Neuroradiol 2006; 27: 769-73.
25. Arnold M, Schroth G, Nedeltchev K, et al. Intra-arterial thrombolysis in 100 patients with acute stroke due to middle cerebral artery occlusion. Stroke 2002; 33: 1828-33. (Pubitemid 34761070)
26. Brekenfeld C, Remonda L, Ndedltchev K, et al. Symptomatic intracranial hemorrhage after intra-arterial thrombolysis in acute ischemic stroke: assessment of 294 patients treated with urokinase. J Neurol Neurosurg Psychiatry 2007; 78: 280-5.
27. Ueda T, Sakaki S, Kumon Y, Ohta S. Multivariate analysis of predictive factors related to outcome at 6 months after intra-arterial thrombolysis for acute ischemic stroke. Stroke 1999; 30: 2360-5. (Pubitemid 29517735)
28. Pannel R, Gurewich V. Pro-urokinase: a study of its stability in plasma and of a mechanism for its selective fibrinolytic effect. Blood 1986; 67: 1215-23. (Pubitemid 16080585)
29. Furlan A, Higashida R, Weschsler L, et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial, prolyse in acute cerebral thromoblembolism. JAMA 1999; 282: 2003-11.
30. Zhang L, Zhang ZG, Zhang C, Zhang RL, Chopp M. Intravenous administration of a GPIIb/IIIa receptor antagonist extends the therapeutic window of intraarterial tenecteplase-tissue plasminogen activator in a rat stroke model. Stroke 2004; 35: 2890-95.
31. Lopez-Atalaya JP, Roussel BD, Ali C, et al. Recombinant Desmodus rotundus salivary mechanism without exerting neurotoxic effects. Stroke 2007; 38: 1036-43.
32. Vanderschueren S, Van Vlaenderen I, Collen D. Intravenous thrombolysis with recombinant staphylokinase versus tissue-type plasminogen activator in a rabbit embolic stroke model. Stroke 1997; 28: 1783-8. (Pubitemid 27391450)
33. Ahmed N, Nasman P, Wahlgren NG. Effect of intravenous nimodipine on blood pressure and outcome after acute stroke. Stroke 2000; 31: 1250-5. (Pubitemid 30351241)
34. Fitt GJ, Farrar J, Baird AE, et al. Intra-arterial streptokinase in acute ischemic stroke: a pilot study. Med J Aust 1993; 159: 331-4. (Pubitemid 23266144)
35. Lapchak PA. Development of thrombolytic therapy for stroke: a perspective. Expert Opin Invest Drugs 2002; 11: 1623-32.
36. Lapchak PA, Araujo DM, Pakola S, Song D, Wei J, Zivin JA. Microplasmin: a novel thrombolytic that improves behavioral outcome after embolic strokes in rabbits. Stroke 2002; 33: 2279-84. (Pubitemid 35014643)
37. Hacke W, Kaste M, Bluhmki E, et al.; ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. NEJM 2008; 359: 1317-29.
38. Ogawa A, Mori E, Minematsu K, et al. Randomized trial of intra-arterial infusion of urokinase witin 6 hours of middle cerebral artery stroke: the middle cerebral artery embolism local fibrinolytic intervention trial (MELT) Japan. Stroke 2007; 38: 2633-9.
39. Saver JL. Intra-arterial fibrinolysis for acute ischemic stroke: the message of MELT. Stroke 2007; 38: 2627-8.
40. Ducrocq X, Bracard S, Tailandier L, et al. Comparison of intravenous and intra-arerial urokinase thrombolysis for acute ischemic stroke. J Neuroradiol 2005; 32: 26-32.
41. Mattle HP, Arnold M, Georgiadis D, et al. Comparison of intra-arterial and intra-venous thrombolysis for ischemic stroke with hyperdense middle cerebral artery sign. Stroke 2008; 39: 379-83. (Pubitemid 351619459)
42. Qureshi AI, Ezzeddine MA, Nasar A. Is IV tissue plasminogen activator beneficial in patients with hyperdense artery sign? Neurology 2006; 66: 1171-4.
43. Furlan AJ. Natural history of atherothromboembolic occlusion of cerebral arteries: carotid versus vertebrobasilar territories. In: Hacke W, del Zoppo GJ, Hirschberg M (eds). Thrombolytic therapy in acute ischaemic stroke. New York: Spinger-Verlag 1991; 71-6.
44. Hacke W, Zeumer H, Ferbet A, Bruckmann H, del Zoppo GJ. Intra-arterial thrombolytic therapy improves outcome in patients with acute vertebrobasilar occlusive disease. Stroke 1988; 19: 1216-22.
45. Huemer M, Niederwieser V, Ladurner G. Thrombolytic treatment for acute occlusion of the basilar artery. J Neurol Neurosurg Psychiatry 1995; 58: 227-8.
46. Becker KJ, Monsein LH, Ulatowski J, Mirski M, Williams M, Hanley DF. Intra-arterial thrombolysis in vertebrobasilar occlusion. AJNR Am J Neuroradiol 1996; 17: 255-62.
47. Cross DT, Moran CIJ, Akins PT, Angtuaco EE, Diringer MN. Relationship between clot location and outcome after basilar artery thrombolysis. AJNR 1997; 18: 1221-28.
48. Lewandowski CA, Frankel M, Tomsick TA, et al. Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy in acute ischemic stroke: Emergency Management of Stroke (EMS) Bridgiing Trial. Stroke 1999; 30: 2598-605.
49. The Interventional Management of Stroke (IMS) II Study. Stroke 2007; 38: 2127-35.
50. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: The European Cooperative Acute Stroke Study (ECASS). JAMA 1995; 274: 1017-25.
51. Hacke W, Kaste M, Fieschi C, et al. Randomized double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischemic stroke (ECASS II): Second European-Australasian Acute Stroke Study Investigators. Lancet 1998; 352: 1245-51.
52. Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial, Alteplase Thromoblysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA 1999; 282: 2019-26.
53. Hacke W, Donnan G, Fieschi C, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS and NINDS rt-PA stroke trials. Lancet 2004; 363: 768-74.
54. rd, Mandrekar JN, Schleck CD, Thielen KR, Kallmes DF. Complications of diagnostic cerebral angiography: evaluation of 19,826 consecutive patients. Radiology 2007; 243: 812-9.
55. Abciximab Emergent Stroke Treatment Trial Investigators. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of a randomized phase 2 trial. Stroke 2005; 36: 880-90.
56. Smith WS, Sung G, Starkman S, et al. Safety and efficacy of mechanical embolectomy in acute ischemic stroke: results of the MERCI trial. Stroke 2005; 36: 1432-8.
57. Becker K. Endovascular treatment of acute stroke. Current treatment options in neurology 2007; 21: 70-6.
58. Smith WS. Safety of mechanical thrombectomy and intrravenous tissue plasminogen activator in acute ischemic stroke. Results of the multi Mechanical Embolus Removal in Cerebral Ischemia (MERCI) trial, part I. AJNR Am J Neuroradiol 2006; 27: 1177-82.
59. Smith WS, Sung G, Saver J, et al. Mechanical thrombectomy for acute ischemic stroke: final results of the multi merci trial. Stroke 2008; 39: 1205-12. (Pubitemid 351440692)
60. Alexandrov AV, Wojner AW, Grotta JC; CLOTBUST Investigators. CLOTBUST: design of randomized trial of ultrasound-enhanced thrombolysis for acute ischemic stroke. J Neuroimaging 2004; 14: 108-12.
61. Bose A, Henkes H, Alfke K, et al.; Penumbra phase I stroke trial investigators. JNR Am J Neuroradiol 2008; 29: 1409-13.
62. Arnold M, Nedeltchev K, Schroth G, et al. Clinical and radiological predictors of recanalization and outcome of 40 patients with acute basilar artery occlusion treated with intra-arterial thromoblysis. J Neurol Neurosurg Psychiatry 2004; 75: 857-62.
63. Saqqur M, Uchino K, Demchuk AM, et al. Site of arterial occlusion identified by transcranial Doppler predicts the response to intravenous thrombolysis for stroke. Stroke 2007; 38: 948-54. (Pubitemid 46568457)
64. Linfante I, Llinas RH, Selim M, et al. Clinical and vascular outcome in internal carotid artery versus middle cerebral artery occlusions after intravenous tissue plasminogen activator. Stroke 2002; 33: 2066-71. (Pubitemid 34840069)
65. Flint AC, Cuckwiler GR, Budzik W, et al. Mechanical thrombectomy of intracranial internal carotid occlusion: pooled results of the MERCI and Multi MERCI Part I trials. Stroke 2007; 38: 1274-80.
66. Sorensen AG, Buonanno FS, Gonzalez RG, et al. Hyperacute stroke: evaluation with combined multi section diffusion-weighted and hemodynamically weighted echo-planar MR imaging. Radiology 1996; 199: 391-401.
67. Warach S, Dashe JF, Edelman RR. Clinical outcome in ischemic stroke predicted by early diffusion-weighted and perfusion magnetic resonance imaging: a preliminary analysis. J Cereb Blood Flow Metab 1996; 16: 53-9. (Pubitemid 26007950)
68. Barber PA, Darby DG, Desmond PM, et al. Prediction of stroke outcome with echoplanar perfusion and diffusion weighted MRI. Neurology 1998; 51: 418-26.
69. Tong DC, Yenari MA, Albers GW, O'Brien M, Marks MP, Moseley ME. Correlation of perfusion and diffusion weighted MRI with NIHSS score in acute (< 6.5 hour) ischemic stroke. Neurology 1998; 50: 864-70. (Pubitemid 28212807)
70. Kidwell CS, Alger JR, Di Salle F, et al. Diffusion MRI in patients with transient ischemic attacks. Stroke 1999; 30: 1174-80.
71. Kidwell CS, Saver JL, Mattiello J, et al. Thrombolytic reversal of acute human cerebral ischemic injury shown by diffusion/perfusion magnetic resonance imaging. Ann Neurol 2000; 47: 462-9.
72. Chalela JA, Ezzeddine MA, Calabrese TM, et al. Diffusion and perfusion changes two hours after intravenous rt-PA therapy: a preliminary report. Stroke 2002; 33: 356-7.
73. Schacfer PW, Hussan Khani A, Christopher R, et al. Partial reversal of DWI abnormalities in stroke patients undergoing thrombolysis: evidence of DWI and ADC thresholds. Stroke 2002; 33: 357.
74. Neumann-Haefelin T, Kastrup A, de Crespigny A, et al. Serial MRI after transient focal cerebral ischemia in rats: dynamics of tissue injury, blood-brain barrier damage, and oedema formation. Stroke 2000; 31: 1965-72.
75. Fiehler J, Foth M, Kucinski T, et al. Severe ADC decreases do not predict irreversible tissue damage in humans. Stroke 2002; 33: 79-86.
76. Jansen O, Schellinger PD, Fiebach JR, Hacke W, Sartor K. Early recanalizations in acute ischemic stroke saves tissue at risk defined by MRI. Lancet 1999; 353: 2036-7.
77. Schlaug G, Benfiled A, Baird AE, et al. The ischemic penumbra: operationally defined by diffusion and perfusion MRI. Neurology 1999; 53: 1528-37.
78. Schellinger PD, Jansen O, Fiebach JB, et al. Monitoring intravenous recombinant tissue plasminogen activator thrombolysis for acute ischemic stroke with diffusion and perfusion MRI. Stroke 2000; 31: 1318-28.
79. Schellinger PD, Jansen O, Fiebach JB, et al. Feasibility and practice of MR imaging of stroke in the management of hyperacute cerebral ischemia. AJNR Am J Neuroradiol 2000; 21: 1184-9.
80. Parsons MW, Yang Q, Barber PA, et al. Perfusion magnetic resonance imaging maps in hyperacute stroke: relative cerebral blood flow most accurately identifies tissue destined to infarct. Stroke 2001; 32: 1581-7.
81. Rordorf G, Koroshetz WJ, Copen WA, et al. Regional ischemia and ischemic injury inpatients with acute middle cerebral artery stroke as defined early diffusion-weighted and perfusion-weighted MRI. Stroke 1998; 29: 939-43.
82. Marks MP, Tong D, Beaulieu C, Albers G, deCrespigny A, Moseley ME. Evaluation of early reperfusion and IV rt-PA therapy using diffusion and perfusion weighted MRI. Neurology 1999; 52: 1792-8.
83. Albers GW, Thijs VN, Wechsler LR, et al. Magnetic resonance imaging profiles predict clinical response to early reperfusion: the diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study. Ann Neurol 2006; 60: 508-17.
84. Schellinger PD, Thomalla G, Fielhler J, et al. MRI-based and CT-based thrombolytic therapy in acute stroke within and beyond established time windows. An analysis of 1210 patients. Stroke 2007; 38: 2640-5.